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Abstract
Title: Predicting the Course of Mild Cognitive Impairment in a Memory Disorder
Clinic Sample
Author: Amanda Denny, M.S.
Major Advisor: Anthony LoGalbo, Ph.D.
Objective: The present study examines a number of psychosocial and medical
risk factors for dementia and their association with the outcome of mild cognitive
impairment (MCI) in a memory disorder clinic sample.
Method: Twelve years of archival cognitive testing data from 125 East Central
Florida Memory Disorder Clinic patients was utilized. Participants were included
in this study if they were diagnosed with MCI following initial cognitive testing
and then re-evaluated and diagnosed with either stable MCI, dementia of the
Alzheimer’s type (AD) or mixed dementia (dementia of the Alzheimer’s type and
vascular dementia), or cognition within normal limits. Patients’ medical and
psychosocial information was obtained from their electronic medical records
(EMR) and included as predictors in this present study.
Results: Age of patients (M = 77.2, SD = 6.2) at initial visit was associated with
an increase in the odds of receiving a final diagnosis of dementia, with an odds
ratio of 1.074 (95% CI, 1.014 to 1.137), Wald, χ2(1) = 5.893, p = .015. Individuals
who were diagnosed with amnestic MCI at their initial evaluation were more
likely to convert to dementia (χ2 (18) = 45.65, p < .001). A history of depression
was also associated with an increase in the odds of receiving a final diagnosis of
dementia, with an odds ratio of 3.213 (95% CI, 1.200 to 8.605), Wald, χ2(1) =
iii

5.396, p = .020. The odds of receiving a final diagnosis of dementia were also
significantly higher for patients who had a diagnosis of hypertension, with an
odds ratio of 2.771 (95% CI, 1.240 to 6.197), Wald , χ2(1) = 6.166, p = .013.
Additionally, patients with a history of comorbid depression and hypertension had
increased odds of converting to dementia, with an odds ratio of 8.894 (95% CI,
3.564 to 22.192), Wald, χ2(1) = 21.942, p = < .001. In contrast, patients with a
history of age-related macular degeneration had increased odds of remaining
stable MCI, with an odds ratio of 4.762 (95% CI, 1.115 to 20.333), Wald, χ2(1) =
4.440, p = .035. Conclusion: The results of the present study support previous
literature that suggests advancing age is the largest non-modifiable risk factor for
dementia. Prior research suggesting amnestic MCI patients are more likely to
convert to dementia was also supported. The present study’s findings also suggest
that patients with MCI may be more likely to progress to AD if they have
histories of depression and/or hypertension. This supports previous research that
suggests a relationship between cardiovascular risk factors and mental health
conditions such as depression, with future cognitive impairment. This highlights
the importance of treating modifiable risk factors for dementia, particularly
depression and hypertension, in order to delay the onset of AD in patients who
have MCI. Lastly, the results of this study may assist clinicians in determining
which patients with MCI may be most likely to convert to dementia, with older
patients who have amnestic MCI, depression, and hypertension, being the most
likely to convert.
iv
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1
Introduction
Alzheimer’s disease (AD) is currently the sixth leading cause of death in the
United States, with 5.7 million Americans afflicted with the disease, and 16.1
million Americans providing unpaid care to those afflicted. In 2018, AD cost the
American public an estimated $277 billion in health care costs, with this number
expected to increase to $1.1 trillion by 2050 (Alzheimer’s Association, 2018).
Although there is no cure for AD, its early detection can allow for doctors to
provide some intervention toward preservation of cognitive function, and provide
patients and their families additional time to receive education about the disease
prognosis and make essential arrangements and preparations for end-of-life care.
Mild cognitive impairment (MCI) is defined as an impairment in cognition that is
more severe than expected for normal aging, yet less severe than expected for
dementia, and is now widely considered to be a precursor to dementia (Petersen,
2004; Eshkoor, Hamid, Mun, & Ng, 2015); however, some individuals diagnosed
with MCI can remain stable upon follow-up testing, or even return to normal
cognition (Pandya, Clem, Silva, & Woon, 2016). Early signs of AD often begin in
the MCI stage, but identifying which individuals with MCI will progress to AD is a
challenging task. Even so, the Alzheimer’s Association (2018) estimates that if
individuals who will develop dementia are identified and diagnosed at the MCI
stage, this could save the American public approximately $7.9 trillion in health care
costs. This could also benefit the caregivers of people with AD who are often left
shouldering the financial burden of caregiving for their loved one with AD.
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Review of the Literature
Alzheimer’s Disease
Clinical Definition. Alzheimer’s disease is defined as a degenerative brain
disease characterized by a decline in cognitive skills that interferes with an
individual’s ability to perform daily activities (Alzheimer’s Association, 2018).
According to the 5th edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) the criteria for diagnosis of a major neurocognitive disorder
requires significant decline in cognition based on the concern of the individual or a
reliable informant and clinical assessment, preferably standardized
neuropsychological testing. Additionally, the cognitive deficits must interfere with
the individual’s everyday functioning, such as the ability to perform complex
activities of daily living. For a diagnosis of major neurocognitive disorder due to
Alzheimer’s disease, there must be a significant decline in learning and memory as
well as at least one additional cognitive domain, with these declines gradually yet
steadily progressing in severity. Although clinical diagnosis has become much
more accurate, AD can only be definitively diagnosed upon autopsy. The DSM-5
established criteria for either probable or possible AD, with probable AD diagnosed
when a genetic etiology is evident through family history or genetic testing, and
possible AD diagnosed when a genetic etiology is unsubstantiated (American
Psychiatric Association, 2013).
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The ICD-10 diagnostic criteria are similar to those of DSM-5; however,
ICD-10 criteria for AD include insidious onset and gradual deterioration. It is noted
that the exact onset of symptoms may be difficult to establish, and that while family
members may suddenly realize the severity of a patient’s symptomatology, these
symptoms do not occur suddenly. If symptoms appear suddenly or are
accompanied by other neurological signs to suggest focal damage, such as
hemiparesis, then other diagnoses should be considered. Additionally, other
medical disorders that could be contributing to the symptomatology should be ruled
out, such as hypothyroidism, normal pressure hydrocephalus, vitamin B12
deficiency, etc. Differential diagnoses to consider in the context of AD include
depressive disorder, delirium, other dementias, or intellectual disability (World
Health Organization, 1992).
Overview. Alzheimer’s disease (AD) is the most common cause of
dementia, accounting for 60-80% of dementia cases (Alzheimer’s Association,
2018). Most patients present with initial symptoms of forgetfulness, along with
confusion, misplacing items, word-finding difficulties, and geographical
disorientation, which significantly impacts their daily functioning (Alzheimer’s
Association, 2018). AD is gradual in onset and typically develops over 2 to 3 years,
but can be longer (World Health Organization, 1992). The disease was first
described in a Tübingen presentation in 1906 by Alois Alzheimer, who observed
and recorded the symptoms of paranoia, disorientation, delusions, auditory
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hallucinations, paraphasia, and progressive memory loss in a female patient, which
eventually led to the patient becoming incontinent and bed ridden until her death
four and a half years later. Upon post-mortem examination, Alzheimer observed
atrophic and vascular changes in the patient’s brain, as well as neurofibrillary
tangles and amyloid plaques distributed throughout her cortex. These
neuropathological changes are now characteristic of the disease (Alzheimer,
Stelzmann, Schnitzlein, & Murtagh, 1995; Small & Cappai, 2006).
Although the disease was first described in 1906, it was not widely
recognized as a common cause of dementia until the mid to late 1970s. Since that
time, AD has been extensively researched, with great strides made toward
discovering the underlying pathological changes associated with the disease. It is
now believed that the accumulation of extracellular beta-amyloid plaques and
intracellular tau protein tangles that consist of paired helical filaments are major
contributing factors to the disease, and that these pathological changes begin to take
place several years before the clinical symptoms of the disease appear.
Neurochemical changes are also noted in AD, which include reduced activity of the
enzyme choline acetyltransferase, reduction of the neurotransmitter acetylcholine,
and reduction of other neurotransmitters and neuromodulators. These changes
eventually lead to chronic inflammation and progressive atrophy of the brain,
which is reflected in the progressive decline of cognitive and functional abilities

5

observed in AD (World Health Organization, 1992; Alzheimer’s Association,
2018).
As the neurons in the brain of a patient with AD are progressively damaged
or destroyed, the individual’s cognitive functioning progressively declines (World
Health Organization, 1992; Alzheimer’s Association, 2018). Initially, neuronal
reduction takes place primarily in the hippocampus, substantia innominate, locus
coeruleus, and the temporoparietal and frontal cortex (World Health Organization,
1992). Eventually, neurons in other areas of the brain that are involved in more
basic functions, such as walking and swallowing, become damaged or destroyed,
and the individual is no longer able to perform these functions independently. In
the final stages of AD, the individual becomes bed-bound and requires 24/7 care
(Alzheimer’s Association, 2018). While the clinical features of AD often progress
in tandem with the accompanied brain changes, there are cases in which one may
present with little evidence of the other (World Health Organization, 1992).
An autopsy study conducted by Schneider, Arvanitakis, Leurgans, &
Bennett (2009) demonstrated that approximately 87.7% of AD cases exclusively
exhibited the characteristic Alzheimer’s pathology, neurofibrillary tangles and
amyloid plaques, while 45.8% showed pathologies related to other dementias,
along with AD pathologies. This is termed mixed pathology, or mixed dementia
when it is diagnosed pre-mortem. The most common form of mixed dementia is
AD combined with vascular dementia. Vascular dementia involves brain damage
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resulting from blocked blood vessels and lacunar infarctions. Vascular changes are
commonly found in individuals with AD, with around 50 percent of people
diagnosed with AD showing signs of lacunar infarctions upon autopsy
(Alzheimer’s Association, 2018).
Epidemiology. Approximately 5.7 million people were living with AD in
the United States in 2018, of which 5.5 million were over the age of 65 and
200,000 were under age 65. An estimated 14% of people over age 71 have some
form of dementia. However, according to the Alzheimer’s Association (2018),
these numbers are an underestimate due to the underdiagnosing and underreporting
of AD, so it is likely that the number of people living with dementia in the United
States is much higher. It is further estimated that the number of people with AD
will rise to around 7.1 million in 2025, and to 13.8 million in 2050 if preventative
measures are not established (Hebert, Weuve, Scherr, & Evans, 2013). The
incidence of AD increases remarkably with age. Projections for 2018 revealed
approximately 66,000 new cases of AD in people between the ages of 65 and 74,
compared to 173,000 new cases in people between 75 to 84, and 245,000 new cases
in people age 85 or older (Hebert, Beckett, Scherr, & Evans, 2001). Currently in the
United States, someone develops AD every 65 seconds; however, by 2050, it is
estimated that someone will develop AD every 33 seconds (Alzheimer’s
Association, 2018). The lifetime probability of developing AD at age 45 is an
estimated 1 in 5 for women and 1 in 10 for men (Chêne, et al., 2015).
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Risk factors. Numerous risk factors, both modifiable and non-modifiable,
have been associated with the development of AD. Of the non-modifiable risk
factors, the three greatest contributing factors are advancing age, family history of
AD, and inheritance of the e4 variant of the apolipoprotein E gene (APOE-e4), with
advancing age having the largest contribution (Alzheimer’s Association, 2018).
Most people with AD are diagnosed after age 65, and the risk of developing AD
dramatically increases from 3 percent in individuals aged 65-74 to 32 percent in
individuals over age 85 (Hebert, Weuve, Scherr, & Evans, 2013). Females are also
at greater risk of developing AD than their male counterparts; however, this is
likely attributable to females’ longer lifespans (American Psychiatric Association,
2013). Family history and genetics have also been identified as risk factors for AD.
People who have a family history of one or more family members with AD are at
increased risk of developing the disease themselves (Alzheimer’s Association,
2018).
With regard to the genetic risk factors, there are two subgroups of AD based
on genetic factors: (1) early-onset cases tend to have rare genetic variants with
strong effect sizes, while (2) late-onset cases are often more complex in that they
tend to have multiple common genetic variants with lower effect sizes (Lambert et
al., 2013). Early-onset AD cases typically develop during age 50 to 60 while lateonset cases develop around age 80 to 90 (American Psychiatric Association, 2013).
The strongest genetic risk locus for late-onset AD has been identified as the e4
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allele of the apolipoprotein E gene (APOE-e4). Apolipoprotein functions as a
cholesterol carrier and supports both lipid transport and injury repair in the brain.
Carriers of the APOE-e4 gene can have an estimated 3 to 15-fold increase in risk
for AD (Liu, Liu, Kanekiyo, Xu, & Bu, 2013). APOE-e4 was the first gene to be
discovered as influencing the development of AD and continues to be the most
impactful. It is the second most common form of the APOE gene, with the APOEe3 form being the most common, and the APOE-e2 form the least common. People
who inherit one copy of the APOE-e4 form are about three times more likely to
develop AD, while people who inherit two copies are eight to twelve times more
likely to develop AD. Additionally, people who inherit the APOE-e4 gene tend to
develop AD at a younger age than those who do not inherit this form of the gene. In
contrast, people who inherit the APOE-e2 gene may have a decreased risk of
developing AD compared to people with the e3 and e4 forms (Alzheimer’s
Association, 2018). Over 20 other genetic loci have been identified that contribute
to late-onset AD risk, with more yet to be identified. Some of these loci are unique
to late-onset AD risk, while others, such as genetic variants that affect amyloid
precursor protein (APP) metabolism and amyloid beta (Aβ) processing, are
associated with both late-onset and early-onset AD. Additionally, pathway analyses
have found four function clusters for common genetic variants of AD risk, which
include: (1) APP metabolism/Aβ formation, (2) tau protein binding, (3) lipid
metabolism, and (4) immune response (Kunkle et al., 2019). Additional meta-
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analyses have identified 215 causative genes that potentially influence AD. These
genes are expressed in immune-related tissues and cells, such as the spleen, liver,
and microglia. Positive genetic correlations have been demonstrated between AD
and other medical conditions, including insomnia, depression, diabetes,
schizophrenia, and neuroticism; whereas inverse genetic correlations were found
between AD and educational attainment, childhood cognitive ability, height, and
subjective well being (Jansen et al., 2019).
A host of modifiable risk factors have been associated with the development
of AD, including cardiovascular risk factors such as hypertension, atherosclerosis,
and diabetes, as well as less formal education, depression, decreased social
engagement, high homocysteine levels, high body mass index (BMI) in mid-life,
low BMI in late-life, and history of traumatic brain injury (Alzheimer’s
Association, 2018; Xu et al., 2015). A study of four common cardiovascular risk
factors (smoking, hypertension, diabetes, and high cholesterol) found that having
one of these increased the risk of dementia by 127%, whereas having all four
increased the risk by 237% (Whitmer, Sidney, Selby, Claiborne Johnston, & Yaffe,
2005). It is notable that the presence of risk factors for AD, both modifiable and
non-modifiable, does not guarantee that a person will develop the disease; however,
it does increase the likelihood of developing it (Alzheimer’s Association, 2018).
Mild Cognitive Impairment
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Clinical Definition. The DSM-5 criteria for a mild neurocognitive disorder
(mild cognitive impairment) require evidence of a modest decline in cognitive
functioning in at least one cognitive domain, based on either the individual’s
concern, a reliable informant, or a clinician’s judgment, or based on
neuropsychological assessment. In contrast to a diagnosis of major neurocognitive
disorder, the cognitive deficits that occur as a result of mild neurocognitive disorder
do not impair an individual’s ability to perform complex activities of daily living
(American Psychiatric Association, 2013). Mild cognitive impairment (MCI) can
be classified as amnestic or non-amnestic, depending on whether memory is
affected, and further classified as single or multiple domain, depending on whether
one or more than one cognitive domain is affected. Summarily, there are four
different ways in which MCI can be classified: amnestic MCI, single domain;
amnestic MCI, multiple domain; non-amnestic MCI, single domain; and nonamnestic MCI, multiple domain (Petersen, 2004).
Overview. MCI was initially termed senescent forgetfulness by Kral (1962)
who described two types of forgetfulness, benign and malignant, which differed in
their symptomatology, course, and prognosis. The benign type was described as
forgetfulness of relatively unimportant events, occurring equally between sexes,
and progressing slowly, whereas the malignant type was described as forgetfulness
of recent events, confusion and confabulation, occurring more frequently in
women, progressing rapidly, and often leading to behavioral disturbance and senile
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dementia (Kral, 1962). MCI has been given many names since it was first
described. It has also been called age-associated memory impairment (Crook &
Ferris, 1992), aging-associated cognitive decline (Levy, 1994, as cited in Luck,
Luppa, Briel, & Riedel-Heller, 2010), and cognitively impaired, not demented
(Ebly, Cohen, & Parhad, 1995, as cited in Luck, Luppa, Briel, & Riedel-Heller,
2010).
Although initially developed as a research classification, Petersen (2004)
was integral in the development of clinical criteria for MCI and classification of
MCI as its own diagnostic construct. The DSM-5 allows for the specification of
MCI diagnoses according to empirically derived etiological types, which include
numerous etiologies such as AD, vascular disease, traumatic brain injury, Lewy
body disease, Parkinson’s disease, etc. (American Psychiatric Association, 2013).
The course of MCI can be variable and difficult to predict, with some cases
progressing to dementia, while others remain stable or revert to normal cognition.
Additionally, some cases of MCI may fluctuate between normal cognition, MCI,
and dementia throughout the course of the disorder. The prevalence and incidence
rates of MCI reversion to normal cognition have been found to be higher than rates
of progression, yet the research concerning MCI reversion is relatively limited
when compared to the research of MCI progression (Pandya, Clem, Silva, & Woon,
2016).

12

Epidemiology. Among people age 65 and older, approximately 15-20
percent have MCI (Roberts & Knopman, 2013); however, it is unknown what
proportion of these people have MCI due to AD or some other etiology
(Alzheimer’s Association, 2018). In a systematic review of the literature performed
by Luck, Luppa, Briel, & Riedel-Heller in 2010, the incidence of MCI was found to
vary widely between amnestic and non-amnestic types, as well as single and
multiple domain subtypes. For example, the incidence rate of MCI of any type
ranged from 8.5 to 76.8 per 1,000 person-years. The incidence of amnestic MCI,
both single and multiple domain, ranged from 9.9 to 40.6 per 1,000 person-years,
while the incidence of both subtypes of non-amnestic MCI ranged from 28 to 36.3
per 1,000 person-years. With regard to amnestic MCI single domain, the incident
rate ranged from 8.5 to 14. Research concerning the incidence rates of amnestic
MCI multiple domain, non-amnestic MCI multiple domain, and non-amnestic MCI
single domain is limited; however, Manly et al. (2008) found incident rates of 9 per
1,000 person-years for amnestic MCI multiple domain, while the incidence rates of
non-amnestic single domain and non-amnestic multiple domain were 23 and 5 per
1,000 person-years, respectively.
Risk factors. The risk factors for the development of MCI tend to mirror
the risk factors for AD; however, there is some variation between the risk factors
for AD and MCI, as well as between risk factors for MCI types. In keeping with the
risk for developing AD, the risk for developing MCI increases with age.
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Additionally, individuals with lower education are also at increased risk for MCI,
as are individuals with a history of vascular diseases such as hypertension, stroke,
and atrial fibrillation (Luck, Luppa, Briel, & Riedel-Heller, 2010). Likewise,
diabetes has also been found to be a risk factor for MCI (Cheng, Huang, Deng, &
Wang, 2012). In contrast, although the APOE ε4 allele is a well-known risk factor
for AD, it was not found to be a significant risk factor for MCI in a systematic
review of the literature (Luck, Luppa, Briel, & Riedel-Heller, 2010).
Predictor Variables
A number of predictors were included in this study. These predictors were
chosen based upon a review of the literature and assessment of which predictors are
significant risk factors for the progression of MCI to AD. Some predictors were
included due to the relatively limited research available regarding their association
with MCI outcome. The following variables were included as predictors of MCI
outcome. Background information, rationale for inclusion, and a description of how
each variable was measured will also be provided.
Marital Status. Research examining how marital status may affect dementia
risk is limited and somewhat contradictory. De Giorgi et al. (2016) conducted a
minireview of 7 studies examining the relationship between marital status and
cognitive impairment. Of these, two studies examined risk of any cause dementia,
three examined risk of AD, one examined risk of both cognitive impairment and
AD, and one examined risk of cognitive impairment only. The geographical
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locations of these studies were as follows: Sweden, Finland, Taiwan, China, Japan,
United States, and France. The study of Finnish people found that co-habiting with
a partner in mid-life was associated with lower risk of cognitive impairment when
compared to single, separated, and widowed people, and widowhood at both midlife and late-life was associated with increased risk of AD compared to married or
cohabiting people (Håkansson et al., 2009). Similarly, the study of Taiwanese
individuals also revealed an increased risk of dementia in widowers (Fan et al.,
2015), while a Swedish study found an increased risk of dementia in all nonmarried people, including widowed, divorced, and single, with divorced men at
higher risk for dementia than divorced women (Sundström et al., 2016). The
Chinese study also found an increased risk of cognitive impairment in single versus
married individuals, with a statistically significant risk of cognitive impairment
observed only in single men (Feng et al., 2014). In contrast, the French study found
an increased risk of AD in never married individuals only (Helmer et al., 1999, as
cited in De Giorgi et al., 2016), while the American study found no association
between marital status and AD risk (Beard, Kokmen, Offord, & Kurland, 1992). An
individual study by Karlamangla et al. (2009) found that Americans who were
widowed or single/never married were more likely to demonstrated cognitive
decline over time than married Americans. Marital status as a risk factor for
dementia warrants further investigation due to mixed findings regarding its
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association with cognitive impairment. This variable was coded as a nominal
variable with four categories: single/never married, divorced, married, or widowed.
Current living situation. Individuals with a limited social network are at
increased risk for developing a variety of both physical and mental health concerns
(Hatfield, Hirsch, & Lyness, 2013; McCallum, 2019). Older adults living alone
represent a particularly vulnerable group for experiencing lower quality of life as a
function of limited social interaction and loneliness (Bai, Yang, & Knapp, 2016),
which may have implications in the development of cognitive impairment. In a
longitudinal study of 345 elderly individuals with a diagnosis of MCI at baseline,
around 50% developed dementia, 60% of whom were living alone at baseline.
These findings were significant after controlling for sex, age, education, type of
MCI, and antidepressant drug use. Furthermore, the individuals who were living
alone developed dementia approximately one year earlier than those who developed
dementia and were living with someone (Grande et al., 2018); thus, older adults
who live alone may be at increased risk for developing AD, but further research is
needed on this topic to solidify these findings. For the purposes of this study, an
individual’s current living situation was dichotomously defined as alone versus not
alone.
Previous occupation. A population-based study of 10,079 Swedish twins
examined the association between complexity of work and risk of AD. The
researchers defined and measured work complexity in terms of working with data
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(i.e., analyzing, synthesizing, compiling, etc.), working with people (i.e.,
mentoring, supervising, instructing, etc.), and working with things (i.e., operating,
handling, manipulating, etc.). They conducted a case-control analysis, as well as a
cotwin control analysis. The researchers found a reduced risk of AD among
individuals whose occupations involved more complex work with people in the
case-control study, after controlling for age, gender, and education. In the cotwin
design, more complex work with people and data was protective against AD in AD
discordant twin pairs (Andel et al., 2005). Another study of 2,950 elderly French
residents found no association between occupation and AD, with occupation
classified into seven different categories based on France’s National Institute of
Statistics and Economic Studies, which included housewives, farmers,
professionals, craftsmen, and shopkeepers (Helmer et al., 2001). Lastly, a study of
1,353 Italian residents also found no association between AD and previous
occupation. This study also included farmers, housewives, blue collar workers, and
white-collar workers, along with occupations that confer a high risk of toxic
exposures to substances such as fertilizers, plastics, metals, and pesticides
(Ravaglia et al., 2002). Because research into how previous occupation influences
cognition is mixed, this subject warrants further examination. For the proposed
study, the classification of previous occupations will be based upon the O*NET
taxonomy which categorizes jobs into five distinct “zones” according the levels of
experience, education, and job training required for each occupation. The zones
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represent an ordinal classification system, with zone one requiring little experience,
education, and training, while zone five requires extensive experience, education,
and training. The previous occupation of each participant in this study was
measured and coded into one of the five job zones using the online O*NET
database of over 900 different jobs and their associated job zones (ONET
Development, 2019).
History of depression and/or anxiety. Depression and anxiety are two mental
health conditions that are commonly seen in older adults. Some studies have shown
depression as a risk factor for developing dementia, whereas others have had
insignificant or conflicting results. In one such study, depression alone was not
significantly associated with the development of dementia; however, one particular
symptom of depression, apathy, was found to increase the risk of dementia by
almost seven times (Palmer et al, 2010). In contrast, a meta-analysis of case-control
and prospective studies found an increased risk of dementia in individuals with
both recent onset and remote depression (Jorm, 2000). In a case-control study
examining the association of both depression and anxiety with future dementia, a
diagnosis of either depression or anxiety was significantly associated with a future
diagnosis of dementia; however, having a diagnosis of comorbid anxiety and
depression did not increase the odds of having a dementia diagnosis compared to
anxiety or depression alone (Burton, Campbell, Jordan, Strauss, & Mallen, 2013).
Another study examining independent and comorbid anxiety and depression found
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an increased risk of AD in individuals with anxiety or depression alone, with a
stronger association found for anxiety rather than depression. This study also found
an increased risk of AD in individuals with comorbid anxiety and depression
(Burke, Cadet, Alcide, O'Driscoll, & Maramaldi, 2018). For the purposes of this
study, history of depression, anxiety, depression and anxiety, or neither depression
nor anxiety was simply as nominal variables (i.e., 1=depression, 2=anxiety, 3=both
depression and anxiety, and 4=neither depression nor anxiety).
Type of MCI. Because MCI can be categorized as either amnestic or nonamnestic, and further subcategorized as single or multiple domain, it is important to
examine whether the course of MCI differs between categories. Previous research
has demonstrated the type of MCI is predictive of progression to dementia, with
multiple domain MCI having the least favorable prognosis compared to single
domain (Alexopoulos, Grimmer, Perneczky, Domes, & Kurz, 2006). Revaglia et al.
(2006) found a nearly two-fold increase in the risk of conversion from amnestic
MCI to dementia, as compared to non-amnestic MCI. Studies that have examined
the conversion rates of MCI to dementia have had inconsistent results, with rates of
conversion ranging from 10-15% per year in one study (Eshkoor, Hamid, Mun, &
Ng, 2015) to up to 33.6% per year in a meta-analysis of 5 studies (Ward, Tardiff,
Dye, & Arrighi, 2013). Additionally, conversion rates over 2 years’ follow-up
ranged from 9.8% to 36.3% in a meta-analysis of 7 studies, and over 5 years’
follow-up, the conversion rates ranged from 10.6% to 37.8% in a meta-analysis of
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4 studies. The rates of conversion from MCI to AD vary due to diagnostic criteria,
the type of population sampled (clinic-based versus community-based), duration of
time to follow-up, and lack of accounting for the loss of patients to follow-up
(Ward, Tardiff, Dye, & Arrighi, 2013); therefore, the predictive value of the type of
MCI in the progression of dementia merits further research.
As for predictors of the reversion and stability of MCI, research of these
topics has been relatively limited. Canevelli et al. (2017) found an 18% rate of MCI
reversion to normal cognition in a meta-analysis of 25 longitudinal studies. In a
retrospective analysis of 74 MCI patients, Tokuchi et al. (2014) found those with
higher education and higher baseline MMSE scores were more likely to revert to
normal cognition. Han et al. (2012) found an increased likelihood of reversion to
normal cognition for the MCI single domain type in a Korean population, with no
significant differences found between amnestic and non-amnestic subtypes.
Moreover, there appears to be a decreased likelihood of reversion when multiple
amnestic and non-amnestic deficits are present (Loewenstein, Acevedo, Agron, &
Duara, 2007), and when deficits are present on multiple neurocognitive tests within
domains (Loewenstein et al., 2009). Type of MCI was coded as a nominal variable
in this study (i.e., 1=MCI amnestic, multidomain; 2=MCI amnestic, single domain;
3=MCI non-amnestic, multidomain; 4=MCI non-amnestic, single domain).
Prescribed memory medication(s). There are currently a small number of
FDA approved medications available to temporarily slow cognitive decline in
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individuals with AD. These include cholinesterase inhibitors such as donepezil,
rivastigmine tartrate, and galantamine, which slow cognitive decline by increasing
the availability of choline within the central nervous system, and slowing the death
of cholinergic neurons. The NMDA antagonist drug, memantine, slows cognitive
decline in patients with AD by inhibiting damage to hippocampal glutamatergic
neurons involved in synaptic plasticity. This damage typically occurs as a result of
an overabundance of glutamate within the synaptic cleft, leading to excitotoxicity
of the receptors and neuronal cell death (Calabrese, Essner, & Förstl, 2007; Danysz
& Parsons, 2012). Because memantine and the cholinesterase inhibitors have
distinctive neuroprotective effects, a combination of memantine with the
cholinesterase inhibitor, donepezil, has been developed. This combination has been
demonstrated to further slow the progression of cognitive decline in individuals
with AD when compared to a combination of memantine and a placebo or
donepezil and a placebo (Howard et al., 2012). For this study, prescription of
memory medications was coded as a “yes or no” variable.
Cardiovascular Diseases. Cardiovascular diseases such as hypertension,
hyperlipidemia, and diabetes during midlife have been associated with an increased
risk of dementia in late life (Whitmer, Sidney, Selby, Claiborne Johnston, & Yaffe,
2005). Hypertension has long been defined as a blood pressure reading of 140/90
mm Hg or higher. It has also been diagnosed when only the systolic blood pressure
is 140 mm Hg or higher, or when only the diastolic blood pressure is 90 mm Hg or

21

higher (Poulter, Prabhakaran, & Caulfield, 2015). More recently, the numeric
definition of hypertension has become a subject of controversy among the medical
community. In 2017, the American College of Physicians (ACP) and the American
Academy of Family Physicians (AAFP) suggested that physicians should
pharmacologically treat patients age 60 and older when their systolic blood
pressure is 150 mm Hg or higher (Qaseem et al., 2017). However, a short time
later, the American Heart Association (AHA) and the American College of
Cardiology set forth new guidelines defining hypertension as 130/80 mm Hg or
higher, based on the same evidence the ACP and AAFP used to set their guidelines
(Whelton, et al., 2018). With this change in diagnostic criteria, the number of
people with hypertension in the U.S. was estimated to have increased by 31
million. Some researchers voiced concern that this new guideline would mislabel
healthy people as hypertensive and highlighted the negative impact this may have
on patients, as well as the fact that blood pressure is inherently labile and varies
considerably throughout the day. Additionally, since blood pressure tends to
increase with age, the patient’s age should be considered when assessing for
hypertension. Researchers have suggested target blood pressure levels should be
around 100 plus half the patient’s age; therefore, for an 80-year-old patient, target
blood pressure should be below 140 mm Hg, whereas for a 40-year-old patient it
should be below 120 mm Hg (Messerli, Rimoldi, & Bangalore, 2018).

22

The Global Disease Burden Study of 2010 found hypertension to be the
leading risk factor for disease burden and global mortality among both men and
women, representing a 27% increase from its rank as the fourth leading risk factor
in 1990 (Lim et al., 2012). As the global population continues to expand and age,
and developing regions of the world are increasingly exposed to the primary
environmental determinants of hypertension, such as excess sodium, alcohol, and
calorie intake, the number of people affected by hypertension is expected to rise
throughout the world over the next decade (Poulter, Prabhakaran, & Caulfield,
2015). Hypertension has long been considered a modifiable risk factor for
cognitive impairment, with the most robust and consistent evidence found in
observational and longitudinal epidemiological studies (Hughes & Sink, 2016).
Individuals who demonstrate cognitive deficits due to hypertension tend to
underperform on measures of executive function, attention, and processing speed,
while immediate and delayed memory appear relatively better preserved (Spinelli et
al., 2014). Research has demonstrated the highest risk for future cognitive decline
in hypertensive individuals at midlife, indicating that duration and chronicity play a
large role (Taylor et al., 2013; Whitmer, Sidney, Selby, Claiborne, Johnston, &
Yaffe, 2005). Even so, there is inconsistent evidence supporting the effectiveness
of pharmacological treatment of hypertension in reducing the risk of future
cognitive decline (Qiu, Winblad, & Fratiglioni, 2005). Evidence of an association
between hypertension and AD pathology has been found at autopsy, with
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hypertensive individuals demonstrating significant atrophy, along with marked
amounts of neurofibrillary tangles and amyloid-β (Aβ) plaques (Petrovich et al.,
2000). Studies have also shown an association between higher systolic blood
pressure and the number of neurofibrillary tangles (Arvanitakis et al., 2018).
Although evidence of hypertension as a risk factor for cognitive decline is
substantial, some contradictory research has been found. For example, Ravaglia et
al. (2006) found no association between hypertension and conversion of MCI to
AD in a 3-year follow-up study of 165 MCI patients. Therefore, the question of
whether hypertension influences the outcome of MCI, and if so, how strongly,
merits further research.
Hyperlipidemia is a biochemical disorder that can be either inherited or due
to secondary causes. It involves the abnormal elevation of serum cholesterol and/or
triglycerides. Hyperlipidemia is an umbrella term that can be further defined as
hypercholesterolemia if only serum cholesterol is elevated, hypertriglyceridemia if
only triglycerides are elevated, or mixed hyperlipidemia if both cholesterol and
triglycerides are elevated (De Costa & Park, 2017). In a retrospective analysis of
721 individuals, those with a diagnosis of hyperlipidemia at midlife were 42%
more likely to develop dementia in late life (Whitmer, Sidney, Selby, Claiborne,
Johnston, & Yaffe, 2005). Additionally, a population-based study found an
increased risk of AD in individuals with hypercholesterolemia at midlife after
adjusting for age, education, body mass index, stroke, and tobacco and alcohol
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usage (odds ratio = 2.1). This study also found that individuals with both
hypercholesterolemia and hypertension at midlife were at a significantly higher risk
of developing AD in late life than those with just one of these risk factors alone
(odds ratio = 3.5) (Kivipelto et al., 2001).
Individual studies of diabetes as a risk factor for Alzheimer’s disease have
had mixed results. In a comparison of sixteen studies investigating the incidence of
Alzheimer’s disease between diabetics and non-diabetics, ten studies showed no
differences in the incidence rate, whereas six studies showed a significant rate of
incidence among diabetics. A quantitative meta-analysis of all sixteen studies
showed a significantly higher risk of developing AD for diabetic individuals
(Cheng, Huang, Deng, & Wang, 2011). A retrospective cohort study of 8,845
individuals found a 46% increased risk of dementia in diabetics (Whitmer, Sidney,
Selby, Claiborne, Johnston, & Yaffe, 2005). Diabetes has also been shown to
increase the risk of converting to dementia from amnestic MCI, with some
indication that treated diabetics were at lower risk for conversion than untreated
diabetics. Additionally, prediabetes and metabolic syndrome were also predictive
of conversion to dementia from amnestic MCI (Cooper, Sommerlad, Lyketsos, &
Livingston, 2015). For this study, hypertension, diabetes, and hyperlipidemia were
coded as “yes or no” variables.
Ophthalmic conditions. Age-related macular degeneration (AMD) is the
most common cause of blindness among Caucasians within the United States,
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while cataracts and glaucoma are the most common causes among African
Americans (Congdon et al., 2004). AMD, glaucoma, and diabetic retinopathy (DR)
are three degenerative ophthalmic conditions commonly seen in the aging
population, which have also been implicated as potential risk factors for the
development of AD. The risk for AD varies between the three diseases, with
differences in risk also found between recent versus established diagnoses of these
ophthalmic conditions. For example, a recent diagnosis (within < 5 years) of
glaucoma was found to increase risk of AD, with a hazard ratio (HR) of 1.46,
whereas an established diagnosis (>5 years) of glaucoma did not increase the risk
for AD (HR=0.91). In contrast, an established diagnosis of AMD did increase risk
of AD (HR=1.50), while a recent diagnosis did not significantly increase risk
(HR=1.20). However, the risk for AD was increased with both recent (HR=1.67)
and established DR (HR=1.50) (Lee et al., 2018). Of these three conditions, AMD
has received the most attention in the literature for its shared etiological and
pathological similarities with AD.
AD and AMD share many of the same vascular risk factors, including
hypertension (van Leeuwen et al., 2003), atherosclerosis (Casserly & Topol, 2004),
smoking (Klein et al., 1993; Anstey, von Sanden, Salim, & O'Kearney, 2007), and
high serum cholesterol (Hyman et al., 2000). Additionally, both AD and AMD
have strong genetic components, with one major genetic contribution in common:
the APOE gene. As is true with AD, the ε2 and ε4 alleles of the APOE gene have
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been associated with either an increased risk or decreased risk of AMD. However,
while the ε4 allele is associated with increased risk of AD, it is associated with
decreased risk of AMD. Similarly, while the ε2 allele is associated with decreased
risk of AD, it is associated with increased risk of AMD. (McKay et al., 2011, as
cited in Logue et al., 2014). Additionally, accumulations of abnormal extracellular
deposits have been found in both AD and AMD, with Aβ plaques found in AD and
drusen found in AMD. The molecular composition of these extracellular deposits
has been found to be quite similar, with drusen and Aβ having complementary
factor proteins (Dentchev et al., 2003, as cited in Logue et al., 2014). Lastly, an
association between low cognitive function and early-stage AMD has been found
(Baker et al., 2009, as cited in Logue et al., 2014), as has an association between
late-stage AMD and incident AD (Klaver et al., 2009, as cited in Logue et al.,
2014). These findings provide evidence for a common etiological mechanism
between the two diseases (Logue et al., 2014). For the proposed study, these three
ophthalmic conditions were coded separately as “yes or no” variables.
Statement of Purpose
The first objective of this study is to examine the various psychosocial and
medical risk factors that influence the progression of MCI to AD, as well as the
factors that influence the reversion of MCI to cognition WNL, and the factors that
influence the temporal stability of MCI. A similar objective of this study is to
examine which individual risk factors among the various psychosocial and medical
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factors may play the largest role(s) in the progression of MCI to AD. This
information will be useful in determining the likelihood of a given MCI diagnosis
progressing to AD. Additionally, this will assist in formulating treatment plans for
patients diagnosed with MCI and determining which particular risk factors should
be most aggressively treated with the goal of delaying the onset of AD. The data
obtained from this study may also be utilized further in meta-analytic studies
examining risk factors for dementia and predictors of MCI outcome.
Hypotheses
1. Each of the 10 predictors will be independently associated with the
course of MCI.
2. Of the psychosocial factors, current living situation will be most
predictive of AD progression.
3. Of the medical factors, cardiovascular diseases will be most
predictive of AD.
4. The medical predictors will be better predictors of AD than the
psychosocial factors.
5. Participants with a combination of both medical and psychosocial
risk factors will be more likely to progress to AD.
6. Participants who are prescribed memory medications will be more
likely to demonstrate stable MCI.
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Methods
Procedure
Participants for this study were gathered from an archival research database
at the East Central Florida Memory Disorders Clinic (ECFMDC), an outpatient
geriatric medical practice that specializes in diagnosing and treating neurocognitive
disorders. This archival database consists of patient data that has been gathered
over the past 12 years at ECFMDC. Patients are typically referred to the ECFMDC
by their primary care providers due to concerns regarding their memory
functioning. Upon referral, patients are evaluated by an interprofessional
healthcare team. A geriatrician or nurse practitioner conducts a clinical interview,
mental status exam, and medical evaluation, and a social worker obtains the
patient’s psychosocial history and administers a neuropsychological screening tool
such as the Montreal Cognitive Assessment (MoCA). The provider then determines
whether the patient should receive further neuropsychological testing and if so, the
patient is referred for either a brief neuropsychological evaluation (BNE) or a
detailed neuropsychological evaluation (DNE). Following the BNE or DNE, an
interdisciplinary professional team comprised of a geriatrician, neurologist,
neuropsychologist, social worker, pharmacy students, and clinical psychology
doctoral students forms a weekly case review panel, which reviews each patient’s
medical and psychosocial history, neuropsychological and laboratory test results,
and neuroimaging. The case review team then collaborates in determining
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appropriate diagnoses and treatment recommendations for each patient. Patients
were later informed of their diagnoses and treatment recommendations, and some
are recommended for future neuropsychological testing depending on the diagnosis
given. Patient data, to include neuropsychological testing data, treatment
recommendations, and diagnoses, are subsequently entered into a SPSS database by
a trained psychometrist for future research purposes at the East Central Florida
Memory Disorder Clinic.
Participants
Participants were included in this study if 1) after undergoing an initial
BNE or DNE, they were diagnosed with MCI, and 2) they underwent an additional
BNE or DNE after some time and were diagnosed with either stable MCI, AD or
mixed dementia (AD and vascular dementia), or cognition within normal limits
(WNL). Participants were excluded from this study if upon review of their
electronic medical record, it was found that they had a history of severe mental
illness, neurological disorder, or a major stroke. Prior to participating in the BNEs,
the patients included in this study consented to the use of their testing data and
medical information for research purposes at the East Central Florida Memory
Disorder Clinic, and if they were unable to provide consent due to limited cognitive
capacity, it was obtained from the patient’s durable power of attorney. Moreover,
Institutional Review Board (IRB) approval was obtained for this particular
investigation.
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The final sample consisted of 125 participants, 55.2% of whom were males
(n = 69) and 44.8% of whom were females (n = 56). Participants’ ages ranged from
64 to 90 at the time of their initial evaluation (M = 77.2, SD = 6.2). The average
length of time between evaluations was 18.2 months (SD = 11.5) with a range of
5.4 to 61 months. Participants’ highest level of education ranged from 8 to 21 years
(M = 14.2, SD = 2.7), with completion of high school the most frequently obtained
(n = 53 : 42.4%), followed by a bachelor’s degree (n = 27 : 21.6%), graduate
degree (n = 22 : 17.6%), associate’s degree (n = 13 : 10.4%), 8th through 11th grade
(n = 6 : 4.8%), and one year of college (n = 4 : 3.2%). Much of the sample
identified as Caucasian (n = 115; 92%), followed by African American (n = 7;
5.6%), and Asian (n = 1; 0.8%). A small number of participants selected “Other” as
their race (n = 1; 0.8%) or chose not to respond (n = 1; 0.8%). In terms of ethnicity,
participants were mostly non-Hispanic (n = 118; 94.4%), followed by unspecified
ethnicity (n = 4; 3.2%), and Hispanic ethnicity (n = 3; 2.4%). Participants’
demographic information was collected and documented at the time of their initial
evaluation through self-report and/or their electronic medical record (EMR).
Patients’ medical and psychosocial information was subsequently collected from
their EMR.
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Figure 1

Figure 2

The participants were mostly married (n = 85 : 68%), followed by widowed
(n = 27 : 21.6%), divorced (n = 12 : 9.6%), and single/never married (n = 1 : .8%).
Participants were largely living with someone (n = 99 : 79.2%) versus living alone
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(n = 26 : 20.8%). Of the 125 participants included in the final sample, 96 were
diagnosed with amnestic MCI after the initial evaluation while 29 were diagnosed
with non-amnestic MCI.

Figure 3
Of the 96 patients diagnosed with MCI-A after the initial evaluation, 62 were
diagnosed with MCI-A multidomain, and 34 were diagnosed with MCI-A single
domain, while 22 patients were diagnosed with MCI-N multidomain, and only 7
patients were diagnosed with MCI-N single domain.
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Figure 4
Results
Age of Patients at Initial Visit and Final Diagnoses
An ordinal logistic regression was conducted to predict the likelihood of
patients receiving a final diagnosis of WNL, MCI, or AD, based on their age at the
initial visit. An increase in age at initial visit was associated with an increase in the
odds of receiving a final diagnosis of dementia, with an odds ratio of 1.074 (95%
CI, 1.014 to 1.137), Wald, χ2(1) = 5.893, p = .015.
Gender and Final Diagnoses
Of the 69 male participants included in this study, 40 received a
diagnosis of stable MCI upon re-evaluation, while 23 converted to dementia, and 6
reverted to normal cognition. Of the 56 female participants included in this study,
29 remained with a diagnosis of stable MCI, while 23 converted to dementia, and 4
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reverted to normal cognition. An ordinal logistic regression was conducted to
predict the likelihood of patients receiving a final diagnosis of WNL, MCI, or AD,
based on their gender. There was no significant increase in the odds of receiving a
final diagnosis of dementia based on gender; however, the odds of remaining stable
MCI was approaching significance for the male gender, with an odds ratio of 2.096
(95% CI, 0.939 to 4.681), Wald, χ2(1) = 3.260, p = .071.

Figure 5
Race and Ethnicity and Final Diagnoses
An ordinal logistic regression was conducted to predict the likelihood of
patients receiving a final diagnosis of WNL, MCI, or AD, based on their race.
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There was no significant increase in the odds of receiving a final diagnosis of
dementia based on race, p = .998. Additionally, an ordinal logistic regression was
conducted to predict the likelihood of patients receiving a final diagnosis of WNL,
MCI, or AD, based on their ethnicity. Likewise, there was no significant increase in
the odds of receiving a final diagnosis of dementia based on ethnicity, p = .561.
Years of Education and Final Diagnoses
An ordinal logistic regression was conducted to predict the likelihood of
patients receiving a final diagnosis of WNL, MCI, or AD, based on their level of
education. There was no significant increase in the odds of receiving a final
diagnosis of dementia based on education level, p = .563.
Marital Status and Final Diagnoses
Of the 125 participants included in this study, 85 were married (68%), 27
were widowed (21.6%), 12 were divorced (9.6%), and 1 was single/never married
(.8%). Of the 85 married participants, 43 remained stable MCI upon re-evaluation,
while 34 converted to dementia, and 8 reverted to WNL. Of the 27 widowed
participants, 19 remained stable MCI, 7 converted to dementia, and 1 reverted to
normal cognition. Of the 12 divorced participants, 7 remained stable MCI, 4
converted to dementia, and 1 reverted to normal cognition. The 1 single/never
married participant converted to dementia. Due to the limited number of
participants in the single/never married group, this category was not included in the
statistical analyses. A one-way ANOVA was conducted to examine the relationship
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between marital status at the initial evaluation and final diagnosis. Levene’s test
suggested that the assumption of homogeneity of variances for living situation was
not violated, F(121) = 3.29, p = .052. Shapiro-Wilk’s test indicated that the
assumption of normality had been violated for the married group, W(85) = 0.746, p
< .001, the divorced group, W(12) = 0.732, p < .01, and the widowed group, W(27)
= 0.622, p < .001. Therefore, a Kruskal-Wallis H test was conducted to examine
whether the final diagnosis was significantly different between patients who were
married, divorced, or widowed at the time of their initial evaluation. There was no
statistically significant difference in final diagnosis between patients who were
married, divorced or widowed, χ2 (2) = 2.516, p = .284. An ordinal logistic
regression was also conducted to predict the likelihood of patients receiving a final
diagnosis of dementia based on their marital status at the initial evaluation. There
was no significant increase in the odds of receiving a final diagnosis of dementia
based on a marital status of married (p = .840), divorced (p = .648), or widowed (p
= .338). Hypothesis 1 was not supported.
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Figure 6
Living Situation and Final Diagnoses
A one-way ANOVA was conducted to examine the relationship between
living situation and final diagnosis. Levene’s test suggested that the assumption of
homogeneity of variances for living situation was violated, F(122) = 3.29, p = .041.
Shapiro-Wilk’s test indicated that the assumption of normality had also been
violated for both the living alone group, W(26) = 0.697, p < .001, and the not living
alone group, W(99) = 0.727, p < .001. Therefore, a Kruskal-Wallis H test was
conducted to examine whether the final diagnosis was significantly different
between patients who were living alone at the time of their initial evaluation and
patients who were not living alone. There was no statistically significant difference
in final diagnosis between patients living alone and patients not living alone, χ2 (2)
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= 1.610, p = .45. An ordinal logistic regression was also conducted to predict the
likelihood of patients receiving a final diagnosis of WNL, MCI, or AD, based on
their living situation. There was no significant increase in the odds of receiving a
final diagnosis of dementia based on living situation, p = .756. Hypothesis 2 was
not supported.
Previous Occupation and Final Diagnoses
Of the 125 participants included in this sample, 5 held a previous occupation
categorized in job zone 1 (little or no preparation needed), 23 had previous
occupations in job zone 2 (some preparation needed), 38 held occupations in job
zone 3 (medium preparation needed), 47 held jobs in job zone 4 (considerable
preparation needed), and 12 had occupations in job zone 5 (extensive preparation
needed). An ordinal logistic regression was conducted to predict the likelihood of
patients receiving a final diagnosis of WNL, MCI, or AD, based on their previous
occupation. There was no significant increase in the odds of receiving a final
diagnosis of dementia based on previous occupation in zone 1 (p = .147), zone 2 (p
= .394), zone 3 (p = .172), or zone 4 (p = .373), compared to zone 5.

39

Figure 7
Time Between Evaluations and Final Diagnoses
The time between the initial evaluation and final evaluation ranged from 5.4
to 61 months (M = 18.2, SD = 11.5). A multiple logistic regression was conducted
to examine whether the time between evaluations predicted participants’ final
diagnosis. Time between evaluations was not a significant predictor of the final
diagnoses of dementia (b = .01, p = .61) or normal cognition (b = -.02, p = .66),
with a reference category of MCI.
History of Depression and/or Anxiety at Initial Visit and Final Diagnoses
Of the 125 patients included in this study, 31 had a history of depression
alone, 12 had a history of anxiety alone, 46 had a history of both anxiety and
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depression, and 36 had no history of either anxiety or depression. Out of the 31
patients who had a history of depression, 16 remained stable MCI upon reevaluation, while 10 converted to dementia, and 5 reverted to WNL. Of the 12
patients with a history of anxiety, 6 remained stable MCI, while 5 converted to
dementia, and only 1 reverted to WNL. Of the 46 patients with a history of both
depression and anxiety, 24 remained stable MCI, while 20 converted to dementia,
and 2 reverted to WNL. Of the 36 patients with no history of depression or anxiety,
23 remained stable MCI, 11 converted to dementia, and 2 reverted to WNL.
A one-way ANOVA was conducted to examine the relationship between
depression and/or anxiety history and final diagnosis. Levene’s test revealed that
the assumption of homogeneity of variances was violated for the variables of
depression, F(6) = 6.04, p < .001, anxiety, F(6) = 4.02, p < .01, both depression and
anxiety, F(6) = 6.13, p < .001, and neither depression nor anxiety, F(6) = 8.29, p <
.001. Shapiro-Wilk’s test indicated that the assumption of normality had also been
violated for depression, W(31) = 0.320, p < .001, anxiety, W(12) = 0.309, p < .01,
both depression and anxiety, W(46) = 0.335, p < .001, and neither depression nor
anxiety, W(36) = 0.394, p < .001. A Kruskal-Wallis H test showed that there was a
statistically significant difference in final diagnosis for patients with a history of
depression at their initial evaluation χ2(6) = 23.996, p = .001. The mean ranks of
each group were 51.67 for MCI-A, 58.64 for dementia, 75 for MCI-N, and 78.33
for normal cognition. This suggests that participants with a history of depression
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were more likely to obtain a final diagnosis of MCI-A or dementia compared to
MCI-N or normal cognition.
An ordinal logistic regression was also conducted to examine the odds of
receiving a final diagnosis of dementia based on history of anxiety or depression. A
history of depression was associated with a significant increase in the odds of
receiving a final diagnosis of dementia, with an odds ratio of 3.213 (95% CI, 1.200
to 8.605), Wald, χ2(1) = 5.396, p = .020, while a history of anxiety was not
associated with an increase in the odds of receiving a dementia diagnosis, p = .796.
Additionally, a history of both depression and anxiety was not associated with an
increase in the odds of receiving a dementia diagnosis, p = .286.

Figure 8
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Type of MCI at Initial Visit and Final Diagnoses
Following the subsequent evaluation, 69 of the 125 patients (55.2%)
remained stable MCI while 46 patients (36.8%) converted to dementia, and only 10
patients (8%) reverted to normal cognition. Of the 69 patients who remained stable
MCI, 32 were diagnosed with MCI amnestic type, multi-domain at their first visit,
while 17 were diagnosed with MCI amnestic type single domain, 17 were
diagnosed with MCI non-amnestic type multi-domain, and 3 were diagnosed with
MCI non-amnestic type, single domain. Of the 46 patients who converted to
dementia, 26 were diagnosed with MCI amnestic type, multi-domain, 13 were
diagnosed with MCI amnestic type, single domain, 4 were diagnosed with MCI
non-amnestic type, multi-domain, and 3 were diagnosed with MCI non-amnestic
type, single domain. Of the 10 patients who reverted to normal cognition, 4 were
diagnosed with MCI, amnestic type, multi-domain, 4 were diagnosed with MCI,
amnestic type, single domain, 1 was diagnosed with MCI non-amnestic type, multidomain, and 1 was diagnosed with MCI, non-amnestic type, single domain.
A chi-square test of independence was conducted to examine the
relationship between amnestic MCI and non-amnestic at the initial evaluation and
final diagnosis. The relationship between initial MCI type and final diagnosis was
significant (χ2 (18) = 45.65, p < .001). Individuals who were diagnosed with
amnestic MCI at their initial evaluation were more likely to receive a final
diagnosis of dementia upon re-evaluation, compared to individuals who were
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diagnosed with non-amnestic MCI at their initial evaluation. Additionally, an
ordinal logistic regression was conducted to examine the odds of receiving a final
diagnosis of dementia based on the subtypes of amnestic and non-amnestic MCI at
the first evaluation. There was no significant increase in the odds of receiving a
final diagnosis of dementia based on an initial diagnosis of MCI amnestic, multidomain, p = .091, MCI amnestic, single domain, p = .210, or MCI non-amnestic,
multi-domain, p = .118.

Figure 9
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Figure 10
Memory Medications and Final Diagnoses
Of the 125 patients included in this sample, 51 were prescribed memory
medications after their initial evaluation while 74 were not. Of the 51 patients
prescribed memory medications, 27 remained stable MCI following re-evaluation,
while 22 converted to dementia, and 2 reverted to WNL. Of the 74 patients who
were not prescribed memory medications, 42 remained stable MCI, 24 converted to
dementia, and 8 reverted to WNL. An ordinal logistic regression was conducted to
predict patients’ final diagnoses based on whether they were prescribed memory
medications after their initial diagnoses. There was no significant increase or
decrease in the odds of receiving a diagnosis of dementia based on prescription of
memory medications, p = .529. Additionally, there was no significant increase in
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the odds of receiving a final diagnosis of stable MCI for patients who were
prescribed memory medications, p = .673; therefore, hypothesis 3 was not
supported.

Figure 11
Cardiovascular Diseases and Final Diagnoses
Hypertension. Of the 125 participants included in this study, 96 had a diagnosis of
hypertension documented in their medical record while 29 did not. Of the 96
patients with a diagnosis of hypertension, 52 remained stable MCI, 36 converted to
dementia, and 8 reverted to WNL. Of the 29 patients without a diagnosis of
hypertension, 17 remained stable MCI, 10 converted to dementia, and 2 reverted to
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WNL. An ordinal logistic regression was conducted to predict the odds of receiving
a final diagnosis of dementia based on patients’ diagnosis of hypertension at the
initial visit. The odds of receiving a final diagnosis of dementia were significantly
higher for patients who had a diagnosis of hypertension, with an odds ratio of 2.771
(95% CI, 1.240 to 6.197), Wald , χ2(1) = 6.166, p = .013, compared to patients
without a diagnosis of hypertension. Hypothesis 4 was supported.

Figure 12
Diabetes. Of the 125 participants included in this study, 35 had a diagnosis of
diabetes in their medical record while 90 did not. Of the 35 patients with a
diagnosis of diabetes, 20 remained stable MCI, 13 converted to dementia, and 2
reverted to WNL. Of the 90 patients without a diagnosis of diabetes, 49 remained
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stable MCI, 33 converted to dementia, and 8 reverted to WNL. An ordinal logistic
regression was conducted to predict the odds of receiving a final diagnosis of
dementia based on patients’ diagnosis of diabetes at the initial visit. There was no
significant difference in the odds of receiving a final diagnosis of dementia based
on a diagnosis of diabetes, p = .838.

Figure 13
Hyperlipidemia. Of the 125 participants included in this study, 87 had a diagnosis
of hyperlipidemia in their medical record while 38 did not. Of the 87 patients with
a diagnosis of hyperlipidemia, 51 remained stable MCI, 31 converted to dementia,
and 5 reverted to WNL. Of the 38 patients without a diagnosis of hyperlipidemia,
18 remained stable MCI, 15 converted to dementia, and 5 reverted to WNL. An
ordinal logistic regression was conducted to predict the odds of receiving a final
diagnosis of dementia based on patients’ diagnosis of hyperlipidemia at the time of
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their initial visit. There was no significant difference in the odds of receiving a final
diagnosis of dementia based on a diagnosis of hyperlipidemia, p = .251.

Figure 14
Ophthalmic Conditions and Final Diagnoses
Diabetic retinopathy. Of the 125 participants included in this study, only one
patient had a diagnosis of diabetic retinopathy in their medical record while 124
patients did not. The patient with diabetic retinopathy remained stable MCI upon
re-evaluation. Due to the limited number of participants with diabetic retinopathy,
this variable was not included in this study’s analyses.
Glaucoma. Out of the 125 participants in this study, 15 patients had a documented
diagnosis of glaucoma while 110 did not. Of the 15 patients with a diagnosis of
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glaucoma, 7 remained stable MCI, 8 converted to dementia, and none reverted to
WNL. Of the 110 patients without a diagnosis of glaucoma, 62 remained stable
MCI, 38 converted to dementia, and 10 reverted to WNL. An ordinal logistic
regression was conducted to predict the odds of receiving a final diagnosis of
dementia based on patients’ diagnosis of glaucoma at the time of their initial visit.
There was no significant difference in the odds of receiving a final diagnosis of
dementia based on a diagnosis of glaucoma, p = .890.

Figure 15
Macular degeneration. Of the 125 participants included in this study, 16 had a
diagnosis of macular degeneration in their medical record while 109 did not. Of the
16 patients with a diagnosis of macular degeneration, 12 remained stable MCI, 4
converted to dementia, and none reverted to WNL. Of the 109 patients without a
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diagnosis of macular degeneration, 57 remained stable MCI, 42 converted to
dementia, and 10 reverted to WNL. An ordinal logistic regression was conducted to
predict patients’ final diagnoses based on patients’ diagnosis of macular
degeneration at the time of their initial visit. There was no significant difference in
the odds of receiving a final diagnosis of dementia based on a diagnosis of macular
degeneration, p = .385. However, there was a significant difference in the odds of
receiving a final diagnosis of stable MCI based on a diagnosis of macular
degeneration, with an odds ratio of 4.762 (95% CI, 1.115 to 20.333), Wald, χ2(1) =
4.440, p = .035.

Figure 16
Hypertension and Depression.
Because hypertension and depression were individually associated with
greater odds of dementia conversion, additional analyses were conducted to
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examine whether patients with a combination of both hypertension and depression
were more likely to convert to dementia after re-evaluation of their cognitive
functioning, compared to individuals with neither hypertension nor depression, or
individuals with depression only or hypertension only. An ordinal logistic
regression was conducted to predict the odds of receiving a final diagnosis of
dementia based on patients’ diagnoses of both hypertension and depression at the
initial visit. The odds of receiving a final diagnosis of dementia were significantly
higher for patients who had a diagnosis of both hypertension and depression, with
an odds ratio of 8.894 (95% CI, 3.564 to 22.192), Wald, χ2(1) = 21.942, p = < .001,
compared to patients without a combination of both hypertension and depression.
Hypothesis 5 was supported.

Figure 17
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Discussion
Developing more insight into which risk factors are associated with the
highest likelihood of MCI progression to dementia is important for healthcare
providers to determine which risk factors should be most aggressively treated with
the goal of delaying the onset of dementia. This is also useful for the formulation of
individualized treatment plans for patients with higher likelihoods of progressing to
dementia. Determining which patients with MCI may be most likely to progress to
dementia will allow patients more time for future care planning and education
regarding the implications of their diagnosis. Additionally, the ability to predict
which cases of MCI will progress to dementia could also save the public healthcare
system trillions of dollars in healthcare costs (Alzheimer’s Association, 2018).
After analyzing the association of psychosocial and medical risk factors for
dementia with the outcome of MCI in a memory disorder clinic sample, it was
found that age, type of MCI at initial evaluation, depression, and hypertension were
associated with an increase in the odds of conversion of MCI to dementia.
Additionally, participants with a history of both depression and hypertension had
even higher odds of converting to dementia compared to participants without a
combination of these risk factors. Macular degeneration was the only risk factor
associated with increased odds of stable MCI; however, the male gender was
approaching significance for increased odds of stable MCI. There were no
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significant associations found between risk factors and reversion of MCI to normal
cognition.
No significant associations were found for the risk factors of marital status,
current living situation, previous occupation, memory medications, and history of
anxiety, hyperlipidemia, diabetes, and glaucoma. For the risk factors of marital
status and current living situation, it may be that people who have been living alone
longer or who have been widowed longer may be more likely to progress to
dementia than patients who are recently widowed or who have been living alone for
a shorter amount of time. Because it was difficult to ascertain the length of time
each patient had been widowed or living alone, this may explain why there were no
significant findings for these risk factors. Conversely, in the minireview conducted
by De Giorgi et al. (2016), marital status was associated with cognitive impairment
in samples of patients in Taiwan, Sweden, China, Finland, Japan, and France;
however, American individuals did not demonstrate an increased rate of cognitive
impairment based on their marital status or their living situation. This may be
related to cultural factors, where American culture tends to be more individualistic
compared to the other cultures included in this minireview, and therefore may
explain the current study’s findings. However, the research is mixed on this topic,
with Karlamangla et al. (2009) finding that widowed and single/never married
individuals in the U.S. declined faster on repeated measures of cognitive testing
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than their married counterparts. Further research on this topic may elucidate this
matter.
Additionally, previous occupation was not associated with MCI outcome.
There are a few possible explanations for this finding. This may be related to how
the variable was measured in this study. The previous occupation of each
participant in this study was coded into one of the five job zones using the online
O*NET database of over 900 different jobs and their associated job zones (ONET
Development, 2019). Although many studies have used this coding system to
investigate work exposures and health related outcomes, the scientific utility of this
system has been relatively understudied and is therefore undetermined at this time
(Cifentes, Boyer, Lombardi, & Punnett, 2010). Moreover, because the O*NET
coding system includes the amount of education required in each job zone, it is
possible that education was a confounding variable in this study, particularly since
this sample was fairly well-educated (M = 14.2, SD = 2.7), with completion of high
school the most frequently obtained education level (n = 53 : 42.4%), followed by a
bachelor’s degree (n = 27 : 21.6%), graduate degree (n = 22 : 17.6%), associate’s
degree (n = 13 : 10.4%), 8th through 11th grade (n = 6 : 4.8%), and one year of
college (n = 4 : 3.2%).
With regard to memory medications, while this study did not find any
impact of these medications on delaying the onset of dementia, there are a few
possible explanations for this finding. Individual randomized clinical trials (RCTs)
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examining the efficacy of memory medications on delaying AD at the MCI stage
have not had significant findings (Feldman et al., 2007; Petersen et al., 2005;
Winblad et al., 2008); however, a meta-analysis of these individual RCTs found
that memory medications did significantly reduce the risk of MCI progression to
AD (Diniz, 2009). This suggests that memory medications may have therapeutic
effects despite the lack of such findings in individual studies. Furthermore, in
reviewing patients’ EMR charts, it appeared that many patients were not prescribed
memory medications immediately following their MCI diagnosis. Rather, these
patients were prescribed memory medications during follow-up visits in which
their cognitive functioning had demonstrated some decline but they were not yet
referred for a re-evaluation of their cognitive functioning. These patients may have
already declined to such an extent that memory medications were not as efficacious
in delaying the onset of AD. If the patients had been prescribed these medications
immediately following their MCI diagnosis, perhaps the patients would have been
more likely to demonstrate stable MCI upon re-evaluation.
With regard to glaucoma, while there was no significant association found
with this risk factor, this might be a function of whether the diagnosis was recent or
established. People with a recent diagnosis of glaucoma are more likely to develop
AD, whereas people with an established diagnosis are not at increased risk (Lee et
al., 2018). It is uncertain how many patients with glaucoma in this study had a
recent diagnosis and how many had an established diagnosis. If a larger number of
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these patients had an established diagnosis of glaucoma, then this could explain
why there was no significant association between this particular risk factor and
MCI outcome.
With regard to the risk factors of anxiety, hyperlipidemia, and diabetes,
although these conditions have been shown to increase risk for dementia in the
literature, they were not associated with MCI outcome in this current study. This
may be related to the chronicity of the condition, where patients were not
experiencing these conditions long enough to observe any cognitive impact.
Conversely, this could also be related to the severity of the condition and how well
these conditions were being treated. If these conditions were well managed among
the majority of patients in this sample, this could explain why no significant
association was found. Furthermore, the number of patients with anxiety in this
sample was relatively small, with only 12 patients diagnosed with anxiety only. A
larger sample of anxiety patients may have had significant results. It is also worth
noting that anxiety encompasses a wide variety of disorders, such as generalized
anxiety disorder, obsessive-compulsive disorder, panic disorder, and post-traumatic
stress disorder. It is unknown which of these disorders the patients in this study
may have been diagnosed with. Further research may shed light on whether certain
anxiety disorders are more likely to increase risk of AD. It is also possible that for
many patients included in this study who demonstrated stable MCI upon re-
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evaluation, not enough time passed between evaluations to allow people with MCI
to convert to AD or revert to normal cognition.
Although male gender was approaching significance for increased odds of
stable MCI, this may be related to the current study having more male participants
than female participants, overall. Macular degeneration was the only risk factor that
was significantly associated with increased odds of stable MCI. This may be
explained by previous research that shows individuals who have the APOE ε2
allele are at decreased risk of AD, while they are at increased risk of macular
degeneration (McKay et al., 2011, as cited in Logue et al., 2014). However, it is
unknown whether the participants included in this study were carriers of the APOE
ε2 allele. If many of this current study’s participants were carriers of the APOE ε2
allele, this could explain why they were more likely to remain stable MCI upon reevaluation. Additionally, previous research has demonstrated that established
diagnoses of macular degeneration were associated with increased risk of AD,
while recent diagnoses were not associated with increased dementia risk (Lee et al.,
2018). While the number of patients who had recent diagnoses of macular
degeneration is unknown, if a large number of patients in this study were recently
diagnosed with macular degeneration, this could also explain why these patients
were more likely to remain stable upon re-evaluation.
Consistent with previous research, advancing age appears to be the single
most important non-modifiable risk factor for dementia. However, other non-
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modifiable risk factors, such as family history and genetic predisposition, were not
included in this study due to unavailability of the necessary data. Additionally,
MCI type was significantly associated with final diagnoses, where patients with
amnestic MCI were more likely to convert to dementia than patients with nonamnestic MCI. When the MCI types were further sub grouped into single and
multiple domain categories, there was no association found between MCI subtype
and final diagnosis. This suggests that the broader diagnostic categories of amnestic
and non-amnestic MCI may be more clinically useful than their single and multiple
domain subgroups.
Of the modifiable risk factors, both hypertension and depression were
individually found to be significantly associated with conversion to dementia, with
odds ratios of 2.771 and 3.213, respectively. This suggests that patients who
present with cognitive impairment and have a diagnosis of either depression or
hypertension should be informed of the importance of managing these conditions in
order to reduce the risk of developing dementia. Moreover, for participants with a
history of both hypertension and depression combined, the risk of converting to
dementia was much higher, with an odds ratio of 8.894. This indicates that patients
who have a diagnosis of amnestic MCI with comorbid depression and hypertension
should receive more aggressive treatment of these conditions in order to reduce the
risk of progressing to dementia. The information gained from this study may assist
healthcare providers in determining which risk factors should be prioritized when
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developing treatment recommendations for patients with MCI. The information
gained from this study will also be useful for patients who are at increased risk of
developing dementia to allow them and their families more time to begin future
care planning and preparations.
Limitations
There are several limitations of the current study, many of which are related
to the electronic medical record (EMR) system from which the data was collected.
The information in patients’ charts was not always consistently documented in the
appropriate location; therefore, obtaining accurate medical and psychosocial
information for each patient was a time consuming task. Additionally, the timing of
a patient’s diagnosis was not always clear, which made it difficult to determine the
chronicity of particular diagnoses, such as depression, anxiety, hypertension, and
the ophthalmic conditions. Having this information would have been helpful for
determining the impact of these conditions on patients’ final diagnoses, particularly
for conditions where chronicity plays a large role in cognitive functioning.
Likewise, it may have been useful to account for how well certain conditions were
being managed, as patients with well-managed diabetes or hyperlipidemia would
likely demonstrate better cognition than patients in whom these conditions are not
well managed. Furthermore, in regards to patients’ psychosocial information, it was
not always clear how long a patient had been widowed, divorced, or married, or
how long they had been living alone or living with someone. This information
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would have also been useful for assessing the impact of these variables on patients’
final diagnoses. Future studies may consider examining the risk of dementia as a
function of the length of time individuals have been divorced, widowed, or living
alone.
Given the diagnostic groupings required to assess this study’s objectives,
this study used a relatively small sample of participants, with only 7 patients
initially diagnosed with non-amnestic MCI, single domain, and only 10 patients
reverting to normal cognition out of the 125 patients overall. Additionally, a limited
number of patients were diagnosed with ophthalmic conditions and only 1 patient
was diagnosed with diabetic retinopathy. This represents a significant limitation to
the current study’s findings, as a larger sample size may have had more significant
predictors of MCI outcome. Another notable limitation of this study was the lack of
ethnic and racial diversity in this sample. Because the sample is predominantly
Caucasian and non-Hispanic, this restricts the generalizability of this study’s
findings to the general and more diverse population. Future research should
consider these limitations when assessing these data and including these findings in
further meta-analytic research projects. Further research may also be useful in
determining what factors may predict reversion of MCI to normal cognition, as this
current study did not find any association in this area.

61

References
Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C.,
. . . Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to
alzheimer's disease: Recommendations from the national institute on agingalzheimer's association workgroups on diagnostic guidelines for alzheimer's
disease. Dementia, 7(3), 270-279. doi:10.1016/j.jalz.2011.03.008
Alexopoulos, P., Grimmer, T., Perneczky, R., Domes, G., & Kurz, A. (2006).
Progression to dementia in clinical subtypes of mild cognitive impairment.
Dementia and Geriatric Cognitive Disorders, 22(1), 27-34.
doi:10.1159/000093101
Alzheimer A., Stelzmann R. A., Schnitzlein H. N. and Murtagh F. R. (1995). An
English translation of Alzheimer’s 1907 paper, ‘Uber eine eigenartige
Erkankung (sic) der Hirnrinde’.Clin. Anat.8,429–431
Alzheimer's Association (2018). 2018 alzheimer's disease facts and figures.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 14(3),
367-429. doi:10.1016/j.jalz.2018.02.001
American Psychiatric Association (2013). Diagnostic and Statistical Manual of
Mental Disorders (5thed). American Psychiatric Publishing.

62

Andel, R., Crowe, M., Pedersen, N. L., Mortimer, J., Crimmins, E., Johansson, B., .
. . Faculty of Social Sciences. (2005). Complexity of work and risk of
alzheimer's disease: A population-based study of swedish twins. The
Journals of Gerontology. Series B, Psychological Sciences and Social
Sciences, 60(5), 251-258. doi:10.1093/geronb/60.5.P251
Anstey, K. J., von Sanden, C., Salim, A., & O'Kearney, R. (2007). Smoking as a
risk factor for dementia and cognitive decline: A meta-analysis of
prospective studies. American Journal of Epidemiology, 166(4), 367-378.
doi:10.1093/aje/kwm116
Arvanitakis, Z., Capuano, A.W., Lamar, M., Shah, R.C., Barnes, L.L., Bennett,
D.A., & Schneider, J.A. (2018). Late-life blood pressure association with
cerebrovascular and Alzheimer disease pathology. Neurology, 91(6), 517525. doi: 10.1212/WNL.0000000000005951
Bai, X., Yang, S., & Knapp, M. (2016). Social support, loneliness and life
satisfaction in older adults living alone. The Gerontologist, 56(3), 714-714.
doi:10.1093/geront/gnw162.2911
Beard, M.C., Kokmen, E., Offord, K.P., & Kurland, L.T. (1992). Lack of
association between Alzheimer’s disease and education, occupation, marital
status, or living arrangement. Neurology, 42(11), 2063-2068. doi:
https://doi.org/10.1212/WNL.42.11.2063

63

Besser, L. M., Alosco, M. L., Ramirez Gomez, L., Zhou, X., McKee, A. C., Stern,
R. A., . . . Kukull, W. A. (2016). Late-life vascular risk factors and
alzheimer disease neuropathology in individuals with normal cognition.
Journal of Neuropathology & Experimental Neurology, 75(10), 955-962.
doi:10.1093/jnen/nlw072
Burke, S. L., Cadet, T., Alcide, A., O'Driscoll, J., & Maramaldi, P. (2018).
Psychosocial risk factors and alzheimer's disease: The associative effect of
depression, sleep disturbance, and anxiety. Aging & Mental Health, 22(12),
1577-1584. doi:10.1080/13607863.2017.1387760
Burton, C., Campbell, P., Jordan, K., Strauss, V., & Mallen, C. (2013). The
association of anxiety and depression with future dementia diagnosis: A
case-control study in primary care. Family Practice, 30(1), 25-30.
doi:10.1093/fampra/cms044
Calabrese, P., Essner, U., & Förstl, H. (2007). Memantine (ebixa®) in clinical
practice - results of an observational study. Dementia and Geriatric
Cognitive Disorders, 24(2), 111-117.
Canevelli, M., Grande, G., Lacorte, E., Quarchioni, E., Cesari, M., Mariani, C.,
Bruno, G., & Vanacore, N. (2016). Spontaneous reversion of mild cognitive
impairment to normal cognition: A systematic review of literature and
meta-analysis. Journal of the American Medical Directors Association,
17(10), 943-948. doi:10.1016/j.jamda.2016.06.020

64

Casserly, I., & Topol, E. (2004). Convergence of atherosclerosis and alzheimer's
disease: Inflammation, cholesterol, and misfolded proteins. The Lancet,
363(9415), 1139-46. doi:10.1016/S0140-6736(04)15900-X
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. A., Dufouil, C., & Seshadri, S.
(2015). Gender and incidence of dementia in the framingham heart study
from mid-adult life. Alzheimer's & Dementia: The Journal of the
Alzheimer's Association, 11(3), 310-320. doi:10.1016/j.jalz.2013.10.005
Cheng, G., Huang, C., Deng, H., & Wang, H. (2012). Diabetes as a risk factor for
dementia and mild cognitive impairment: A meta-analysis of longitudinal
studies. Internal Medicine Journal, 42(5), 484-491. doi:10.1111/j.14455994.2012.02758.x
Cifentes, M., Boyer, J., Lombardi, D.A., & Punnett, L. (2010). Use of O*NET as a
job exposure matrix: a literature review. American Journal of Industrial
Medicine, 53(9), 898-914. doi: 10.1002/ajim.20846
Congdon, N., O’Colmain, B., Klaver, C.C., Klein, R., Munoz, B., Friedman, D.S.,
Kempen, J., Taylor, H.R., Mitchell, P., 2004. Causes and prevalence of
visual impairment among adults in the United States. Arch. Ophthalmol.
122, 477-485. http://dx.doi.org/10.1001/archopht.122.4.477.
Crook, T. H., & Ferris, S. H. (1992). Age associated memory impairment. British
Medical Journal, 304(6828), 714-714. doi:10.1136/bmj.304.6828.714-b

65

Danysz, W. & Parsons, C. G. (2012), Alzheimer's disease, β‐amyloid, glutamate,
NMDA receptors and memantine – searching for the connections. British
Journal of Pharmacology, 167: 324-352. doi:10.1111/j.14765381.2012.02057.x
Daulatzai, M. A. (2013). Death by a thousand cuts in Alzheimer’s disease:
Hypoxia—The prodrome. Neurotoxicity Research, 24(2), 216-243.
doi:10.1007/s12640-013-9379-2
De Costa, G., & Park, A. (2017). Hyperlipidaemia. Medicine, 45(9), 579-582.
doi:10.1016/j.mpmed.2017.06.002
De Giorgi, A., Fabbian, F., Pala, M., Tiseo, R., Boari, B., Signani, F., . . .
Manfredini, R. (2016). Marital status and dementia: A minireview of
available evidence. European Geriatric Medicine, 7(6), 510-511.
doi:10.1016/j.eurger.2016.05.011
Diniz, B.S. (2009). To treat or not to treat? A meta-analysis of the use of
cholinesterase inhibitors in mild cognitive impairment for delaying the
progression to Alzheimer’s disease. European archives of psychiatry and
clinical neuroscience, 259(4), 248-256. doi: 10.1007/s00406-008-0864-1

66

Emamian, F., Khazaie, H., Tahmasian, M., Leschziner, G. D., Morrell, M. J.,
Hsiung, G. R., . . . Sepehry, A. A. (2016). The association between
obstructive sleep apnea and alzheimer's disease: A meta-analysis
perspective. Frontiers in Aging Neuroscience, 8(78),
doi:10.3389/fnagi.2016.00078
Eshkoor, S. A., Hamid, T. A., Mun, C. Y., & Ng, C. K. (2015). Mild cognitive
impairment and its management in older people. Clinical Interventions in
Aging, 10, 687-693. doi:10.2147/CIA.S73922
Fan, L., Sun, Y., Lee, H., Yang, S., Chen, T., Lin, K., . . . Chiu, M. (2015). Marital
status, lifestyle and dementia: A nationwide survey in taiwan. Plos
One,10(9), e0139154. doi:10.1371/journal.pone.0139154
Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., . . . Lane,
R. (2007). Effect of rivastigmine on delay to diagnosis of alzheimer's
disease from mild cognitive impairment: The InDDEx study. Lancet
Neurology, 6(6), 501-512. doi:10.1016/S1474-4422(07)70109-6
Feng, L., Ng, X., Yap, P., Li, J., Lee, T., Håkansson, K., . . . Ng, T. (2014). Marital
status and cognitive impairment among community-dwelling chinese older
adults: The role of gender and social engagement. Dementia and Geriatric
Cognitive Disorders Extra, 4(3), 375-384. doi:10.1159/000358584

67

Grande, G., Vetrano, D.L., Cova, I., Pomati, S., Mattavelli, D., Maggiore, L., . . .
Rizzuto, D. (2018). Living alone and dementia incidence: A clinical-based
study in people with mild cognitive impairment. Journal of Geriatric
Psychiatry and Neurology, 31(3), 107-113. doi:
10.1177/0891988718774425
Håkansson, K., Rovio, S., Helkala, E., Vilska, A., Winblad, B., Soininen, H., . . .
Kivipelto, M. (2009). Association between mid-life marital status and
cognitive function in later life: Population based cohort study. BMJ,
339(7712), 99-99. doi:10.1136/bmj.b2462
Han, J. W., Kim, T. H., Lee, S. B., Park, J. H., Lee, J. J., Huh, Y., . . . Kim, K. W.
(2012). Predictive validity and diagnostic stability of mild cognitive
impairment subtypes. Alzheimer's & Dementia: The Journal of the
Alzheimer's Association, 8(6), 553-559. doi:10.1016/j.jalz.2011.08.007
Hatfield, J. P., Hirsch, J. K., & Lyness, J. M. (2013). Functional impairment, illness
burden, and depressive symptoms in older adults: Does type of social
relationship matter?: Social support, impairment, illness, and
depression. International Journal of Geriatric Psychiatry, 28(2), 190-198.
doi:10.1002/gps.3808

68

Hebert, L.E., Beckett, L.A., Scherr, P.A., & Evans, D.A. (2001). Annual incidence
of Alzheimer disease in the united states projected to the years 2000
through 2050. Alzheimer Disease and Associated Disorders, 15(4), 169173.
Hebert, L.E., Weuve, J., Scherr, P.A., Evans, D.A. (2013). Alzheimer disease in the
United States (2010-2050) estimated using the 2010 Census. Neurology, 80
(19), 1778-1783. doi: https://doi.org/10.1212/WNL.0b013e31828726f5
Helmer, C., Letenneur, L., Rouch, I., Richard-Harston, S., Barberger-Gateau, P.,
Fabrigoule, C., . . . Dartigues, J. F. (2001). Occupation during life and risk
of dementia in french elderly community residents. Journal of Neurology,
Neurosurgery, and Psychiatry, 71(3), 303-309. doi:10.1136/jnnp.71.3.303
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., . . .
Phillips, P. (2012). Donepezil and memantine for moderate-to-severe
alzheimer's disease. The New England Journal of Medicine, 366(10), 893903. doi:10.1056/NEJMoa1106668
Hughes, T. M., & Sink, K. M. (2016). Hypertension and its role in cognitive
function: Current evidence and challenges for the future. American Journal
of Hypertension, 29(2), 149-157. doi:10.1093/ajh/hpv180
Hyman, L., Schachat, A.P., He, Q., Leske, M.C. (2000). Hypertension,
cardiovascular disease, and age-related macular degeneration. Arch
Ophthalmol, 118(3), 351–358. doi:10.1001/archopht.118.3.351

69

Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S., .
. . Posthuma, D. (2019). Genome-wide meta-anaysis identifies new loci and
functional pathways influencing Alzheimer’s disease risk. Nature Genetics,
51(3), 404-413. doi: https://doi.orh/10.1038/s45188-018-0311-9
Jorm, A.F. (2000). Is depression a risk factor for dementia or cognitive decline? A
review. Gerontology, 46(4), 219-227.
Karlamangla, A. S., Miller-Martinez, D., Aneshensel, C. S., Seeman, T. E., Wight,
R. G., & Chodosh, J. (2009). Trajectories of cognitive function in late life in
the united states: Demographic and socioeconomic predictors. American
Journal of Epidemiology, 170(3), 331-342. doi:10.1093/aje/kwp154
Kivipelto, M., Helkala, E., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen,
K., . . . Nissinen, A. (2001). Midlife vascular risk factors and alzheimer's
disease in later life: Longitudinal, population based study. BMJ, 322 (7300),
1447-1451. doi:10.1136/bmj.322.7300.1447
Klein, R., Klein, B., Linton, K., & DeMets, D.L. (1993). The beaver dam eye
study: The relation of age-related maculopathy to smoking. American
Journal of Epidemiology, 137(2), 190-200.
Kral, V. A. (1962). Senescent forgetfulness: Benign and malignant. Canadian
Medical Association Journal, 86, 257-260.

70

Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., . . .
Boland, A. (2019). Genetic meta-analysis of diagnosed Alzheimer's disease
identifies new risk loci and implicates A[beta], tau, immunity and lipid
processing. Nature Genetics, 51(3), 414-430. doi: 10.1038/s41588-0190358-2
Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez,
C., . . . Amouyel, P. (2013). Meta-analysis of 74,046 individuals identifies
11 new susceptibility loci for Alzheimer’s disease. Nature Genetics, 45(12),
1452-1458. doi: 10.1038/ng.2802
Langa, K. M., & Levine, D. A. (2014). The diagnosis and management of mild
cognitive impairment: A clinical review. Jama, 312(23), 2551-2561.
doi:10.1001/jama.2014.13806
Lee, A. Y., Lee, C. S., Larson, E. B., Gibbons, L. E., McCurry, S. M., Bowen, J.
D., . . . Crane, P. K. (2019). Associations between recent and established
ophthalmic conditions and risk of alzheimer's disease. Alzheimer's &
Dementia: The Journal of the Alzheimer's Association, 15(1), 34-41.
doi:10.1016/j.jalz.2018.06.2856

71

Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani,
M.P.H., . . . Ezzati, M. (2012). A comparative risk assessment of burden of
disease and injury attributable to 67 risk factors and risk factor clusters in
21 regions, 1990–2010: A systematic analysis for the global burden of
disease study 2010. The Lancet, 380(9859), 2224-2260. doi:10.1016/S01406736(12)61766-8
Liu, C.C., Liu, C.C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and
Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol., 9(2),
106-118. doi: 10.1038/nmeurol.2013.32
Loewenstein, D. A., Acevedo, A., Agron, J., & Duara, R. (2007). Stability of
neurocognitive impairment in different subtypes of mild cognitive
impairment. Dementia and Geriatric Cognitive Disorders, 23(2), 82-86.
doi:10.1159/000097304
Loewenstein, D. A., Acevedo, A., Small, B. J., Agron, J., Crocco, E., & Duara, R.
(2009). Stability of different subtypes of mild cognitive impairment among
the elderly over a 2- to 3-year follow-up period. Dementia and Geriatric
Cognitive Disorders, 27(5), 418-423. doi:10.1159/000211803
Logue, M. W., Schu, M., Vardarajan, B. N., Farrell, J., Lunetta, K. L., Jun, G., . . .
Farrer, L. A. (2014). A search for age-related macular degeneration risk
variants in alzheimer disease genes and pathways. Neurobiology of Aging,
35(6), 1510.e7-1510.e18. doi:10.1016/j.neurobiolaging.2013.12.007

72

Luck, T., Luppa, M., Briel, S., & Riedel-Heller, S. G. (2010). Incidence of mild
cognitive impairment: A systematic review. Dementia and Geriatric
Cognitive Disorders, 29(2), 164-175. doi:10.1159/000272424
Manly, J., Tang, M., Schupf, N., Stern, Y., Vonsattel, J. G., & Mayeux, R. (2008).
Frequency and course of mild cognitive impairment in a multiethnic
community. Annals of Neurology, 63(4), 494-506. doi:10.1002/ana.21326
McCallum, E. (2019). Social networks buffer sickness. The Journal of
Experimental Biology, 222(3), jeb192641. doi:10.1242/jeb.192641
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R.,
Kawas, C. H., . . . Phelps, C. H. (2011). The diagnosis of dementia due to
alzheimer's disease: Recommendations from the national institute on agingalzheimer's association workgroups on diagnostic guidelines for alzheimer's
disease. Dementia, 7(3), 263-269. doi:10.1016/j.jalz.2011.03.005
Messerli, F. H., Rimoldi, S. F., & Bangalore, S. (2018). Changing definition of
hypertension in guidelines: How innocent a number game? European Heart
Journal, 39(24), 2241-2242. doi:10.1093/eurheartj/ehx806
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014).
Potential for primary prevention of alzheimer's disease: An analysis of
population-based data. Lancet Neurology, 13(8), 788-794.
doi:10.1016/S1474-4422(14)70136-X

73

O*NET Development. O*NET 23.2 Database. O*NET Resource Center. Retrieved
April 4, 2019, from https://www.onetcenter.org/database.html
Pandya, S. Y., Clem, M. A., Silva, L. M., & Woon, F. L. (2016). Does mild
cognitive impairment always lead to dementia? A review. Journal of the
Neurological Sciences, 369, 57-62. doi:10.1016/j.jns.2016.07.055
Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of
Internal Medicine, 256(3), 183-194. doi:10.1111/j.1365-2796.2004.01388.x
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., .
. . Alzheimer's Disease Cooperative Study Group. (2005). Vitamin E and
donepezil for the treatment of mild cognitive impairment. The New England
Journal of Medicine, 352(23), 2379-2388. doi:10.1056/NEJMoa050151
Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery,
W., . . . Launer, L. J. (2000). Midlife blood pressure and neuritic plaques,
neurofibrillary tangles, and brain weight at death: The HAAS. Neurobiology
of Aging, 21(1), 57-62. doi:10.1016/S0197-4580(00)00106-8
Poulter, N. R., Prabhakaran, D., & Caulfield, M. (2015). Hypertension. The Lancet,
386(9995), 801-812. doi:http://dx.doi.org.portal.lib.fit.edu/10.1016/S01406736(14)61468-9

74

Qaseem, A., Wilt, T.J., Rich, R., Humphrey, L.L., Frost, J., & Forciea, M.A.
(2017). Pharmacologic treatment of hypertension in adults aged 60 years or
older to higher versus lower blood pressure targets: a clinical practice
guideline from the American College of Physicians and the American
Academy of Family Physicians. Ann Intern Med, 166(6), 430-437. doi:
10.7326/M16-1785
Qiu, C., Winblad, B., & Fratiglioni, L. (2005). The age-dependent relation of blood
pressure to cognitive function and dementia. Lancet Neurology, 4(8), 487499. doi:10.1016/S1474-4422(05)70141-1
Rajan, K. B., Barnes, L. L., Wilson, R. S., Weuve, J., McAninch, E. A., & Evans,
D. A. (2018). Blood pressure and risk of incident alzheimer's disease
dementia by antihypertensive medications and APOE ε4 allele. Annals of
Neurology, 83(5), 935-944. doi:10.1002/ana.25228
Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, N., . . .
Mariani, E. (2006). Conversion of mild cognitive impairment to dementia:
Predictive role of mild cognitive impairment subtypes and vascular risk
factors. Dementia and Geriatric Cognitive Disorders, 21(1), 51-8.
doi:10.1159/000089515

75

Ravaglia, G., Forti, P., Maioli, F., Sacchetti, L., Mariani, E., Nativio, V., . . .
Macini, P.L. (2002). Education, occupation, and prevalence of dementia:
Findings from the conselice study. Dementia and Geriatric Cognitive
Disorders, 14(2), 90-100. Retrieved from https://search proquest
com.portal.lib.fit.edu/docview/232496217?accountid=27313
Reitz, C., & Mayeux, R. (2014). Alzheimer disease: Epidemiology, diagnostic
criteria, risk factors and biomarkers. Biochemical Pharmacology, 88(4),
640-651. doi:10.1016/j.bcp.2013.12.024
Roberts, R., & Knopman, D.S. (2013). Classification and epidemiology of MCI.
Clinical Geriatric Medicine, 29(4), 753-772.
Schneider, J.A., Arvanitakis, Z., Leurgans, S.E., & Bennett, D.A. (2009). The
neuropathology of probable Alzheimer disease and mild cognitive
impairment. Ann. Neurol., 66(2), 200-208. doi: 10.1002/ana.21706
Small, D. H., & Cappai, R. (2006). Alois alzheimer and alzheimer's disease: A
centennial perspective. Journal of Neurochemistry, 99(3), 708-710.
doi:10.1111/j.1471-4159.2006.04212.x

76

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M.,
. . . Phelps, C. H. (2011). Toward defining the preclinical stages of
alzheimer's disease: Recommendations from the national institute on agingalzheimer's association workgroups on diagnostic guidelines for alzheimer's
disease. Alzheimer's & Dementia : The Journal of the Alzheimer's
Association, 7(3), 280. doi:10.1016/j.jalz.2011.03.003
Spinelli, C., De Caro, M. F., Schirosi, G., Mezzapesa, D., De Benedittis, L.,
Chiapparino, C., . . . Nazzaro, P. (2014). Impaired cognitive executive
dysfunction in adult treated hypertensives with a confirmed diagnosis of
poorly controlled blood pressure. International Journal of Medical
Sciences, 11(8), 771-778. doi:10.7150/ijms.8147
Sundström, A., Westerlund, O., Kotyrlo, E., Institutionen för psykologi, Enheten
för demografi och åldrandeforskning (CEDAR), Samhällsvetenskapliga
fakulteten, . . . Nationalekonomi. (2016). Marital status and risk of
dementia: A nationwide population-based prospective study from
sweden. BMJ Open, 6(1), e008565. doi:10.1136/bmjopen-2015-008565
Taylor, C., Tillin, T., Chaturvedi, N., Dewey, M., Ferri, C. P., Hughes, A., . . .
Stewart, R. (2013). Midlife hypertensive status and cognitive function
20 Years later: The southall and brent revisited study. Journal of the
American Geriatrics Society, 61(9), 1489-1498. doi:10.1111/jgs.12416

77

Tokuchi, R., Hishikawa, N., Kurata, T., Sato, K., Kono, S., Yamashita, T., . . . Abe,
K. (2014). Clinical and demographic predictors of mild cognitive
impairment for converting to alzheimer's disease and reverting to normal
cognition. Journal of the Neurological Sciences, 346(1), 288-292.
doi:10.1016/j.jns.2014.09.012
Van Leeuwen, R., Ikram, M. K., Vingerling, J. R., Witteman, J. C. M., Hofman, A.,
& de Jong, P. T. V. M. (2004). Blood pressure, atherosclerosis, and the
incidence of age-related maculopathy: The rotterdam study. American
Journal of Ophthalmology, 137(1), 217-217. doi:10.1016/j.ajo.2003.10.013
Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013). Rate of conversion from
prodromal alzheimer's disease to alzheimer's dementia: A systematic review
of the literature. Dementia and Geriatric Cognitive Disorders Extra, 3(1),
320-332. doi:10.1159/000354370
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J.,
Dennison Himmelfarb, C., . . . Wright, J. T. (2018). 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
guideline for the prevention, detection, evaluation, and management of high
blood pressure in adults: Executive summary: A report of the american
college of Cardiology/American heart association task force on clinical
practice guidelines. Journal of the American College of Cardiology, 71(19),
2199-2269. doi:10.1016/j.jacc.2017.11.005

78

Whitmer, R.A., Sidney, S., Selby, J., Claiborne Johnston, S., & Yaffe, K. (2005).
Midlife cardiovascular risk factors and risk of dementia in late life,
Neurology,64(2) 277-281; doi:10.1212/01.WNL.0000149519.47454.F2
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G.K., Truyen, L., . . .
Nye, J.S. (2008). Safety and efficacy of galantamine in subjects with mild
cognitive impairment, Neurology, 70(22), 2024-2035. doi:
10.1212/01.wnl.0000303815.69777.26
World Health Organization (1992). The ICD-10 Classification of Mental and
Behavioral Disorders: Clinical descriptions and diagnostic guidelines.
Geneva: World Health Organization.
Xu, W., Tan, L., Wang, H., Jiang, T., Tan, M., Tan, L., . . . Yu, J. (2015). Metaanalysis of modifiable risk factors for alzheimer's disease. Journal of
Neurology, Neurosurgery and Psychiatry, 86(12), 1299.
doi:http://dx.doi.org.portal.lib.fit.edu/10.1136/jnnp-2015-310548

